We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Prof. Tomris Ozben of Turkey Elected Next President of the IFCC

By LabMedica International staff writers
Posted on 04 Oct 2022

The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC, Milano, Italy) has announced the election of Prof. More...

Tomris Ozben, representing the Turkish Biochemical Society (TBS), as its next President. In the election, Prof. Ozben received 45 votes (58%) from the 77 member societies that voted, out of a total of 89 member societies. Her term in office starts on January 2023 and is scheduled to end on December 2026. Other candidates in the election were Prof. Michael Neumaier (German Society for Clinical Chemistry and Laboratory Medicine; DGKL) and Prof. Tahir Pillay (South African Association for Clinical Biochemistry and Laboratory Medicine; SAACB).

Prof. Ozben, EuSpLM, Ph.D., D.Sc., and Specialist in Clinical Biochemistry, currently serves as President of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM). She has been Chair or a Member in many Federations, Scientific Organizations, Societies, Committees and Councils. She is the Past-IFCC Treasurer, Past-Chair of the IFCC Congress and Conference Committee, Past-President of the Balkan Clinical Laboratory Federation (BCLF), and Board Member of the IFCC Foundation for Emerging Nations (FEN).

Over her tenure at Akdeniz University (Antalya, Turkey), Prof. Ozben has served as Vice Rector, Director of Research Funds, Chair of the Dept. of Clinical Biochemistry, and Founding Director of Central Laboratory at Akdeniz University Hospital. She worked for more than 10 years in the Ethical Committee of Akdeniz University Hospital and Medical Faculty on themes concerning drug research in clinical trials. She served as Commission Member of the Turkish Ministry of Health for restructuring Medical Education and Teaching, as well as Member-Elect of the Turkish High Educational Council for four years.

Prof. Ozben’s own research interests include identification of early markers for diagnosis and prognosis of cancer, cardiovascular and chronic kidney diseases, diabetes, liquid biopsy, proteomics, oxidative stress and antioxidants in health and disease, impact of apoptosis in cancer therapy, multidrug resistance, nanoparticles, therapeutic drug monitoring, development and validation of new tests, analytical techniques, quality control and management, teaching, mentoring, research, and laboratory management.

Prof. Ozben serves as mentor to numerous graduate students and takes part at Post-Graduate Education Programs (Specialty and PhD) at Akdeniz University, PhD program “Clinical Experimental Medicine” at University of Modena and Reggio Emilia and External Examiner for Post-graduate education at University of Zimbabwe. She has received several awards including Akdeniz University “Outstanding Service” and “Science” awards, AACC Van Slyke Society and AACC TDM/Toxicology Division and AACC’s National Academy of Clinical Biochemistry (NACB) awards.

Prof. Ozben is on the Editorial Board of several scientific journals, and a reviewer for several journals, and scientific projects evaluator for the Italian Ministry for University Education and Research (MIUR; CINECA), Ministry of Science and Environmental Protection of Republic of Serbia, Israel Science Foundation, and the Scientific and Technological Research Council of Turkey (TUBITAK). She has taken part in the organization of several WorldLabs, EuroMedLabs, IFCC General Conference, and FEBS-IUBMB Advanced Courses, Workshops and Young Scientists FORUMs. She has published over 250 manuscripts; several book chapters; edited books published by international publishers, and attended as an invited speaker to more than 300 international conferences.

Related Links:
IFCC 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.